During the first day of the 44 th Annual JP Morgan Healthcare Conference in San Francisco, a clear narrative emerged. With ...
Recent performance snapshot Biogen (BIIB) shares closed at US$171.59, with performance mixed across recent periods. The stock shows a 1 day return of about a 1% decline, a 4.4% gain over the past week ...
Biogen's CEO says the company's late-stage pipeline is in good shape, but the drugmaker is still hunting for deals to build ...
Eisai and Biogen recently announced that the U.S. FDA has accepted for Priority Review a supplemental Biologics License Application for LEQEMBI IQLIK, a subcutaneous weekly autoinjector starting dose ...
Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...
Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...
To be a better neuroscience company, Biogen is going to have to diversify—outside of the therapeutic area that has in recent years defined the company. “We always call ourselves a neuroscience company ...
Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...
Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...
Shares of Biogen Inc. slipped 5.04% to $169.31 Wednesday, on what proved to be an all-around grim trading session for the ...
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results